Eiger BioPharmaceuticals (EIGR) Reports 36% Durable Virologic Response at 24-Wk Post-Treatment with Peginterferon Lambda in Phase 2 LIMT HDV Study

April 11, 2019 4:10 PM
Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) today announced end of study post-treatment results of the Phase 2 LIMT HDV Study ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles